Active — Not RecruitingNot Applicable

Impact of COVID-19 on GU Disease

United States15,240 participantsStarted 2021-02-18

Plain-language summary

The purpose of this research study is to identify patients with GU disease with active or past COVID-19 infection. Participants will be asked to: * Complete an Online COVID-19 Questionnaire. * Disclose if the patient has or had Genitourinary cancer or benign urologic condition * Provide urine specimen for research * Provide 4 tablespoons of blood for testing blood for research. * Provide permission to access medical records, such as patient lab results, medical history, imaging reports, etc.

Who can participate

Age range40 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Subjects must be men and women 40 years of age or older * Subjects at risk or with GU cancer (Prostate, Bladder, Kidney) * Subjects with benign GU disorders ( BPH, UTI, Bladder infection and kidney stone) * Subjects must have a GU disease that requires clinic visit as determined by physician or healthcare provider following a telehealth appointment * Willing and able to provide blood and urine samples * Willing and able to complete a questionnaire to determine the COVID-19 symptoms. * Willing and able to sign informed consent form Exclusion Criteria: * Men and women below 40 years of age * Subjects do not have a GU disease

What they're measuring

Proportion of patients with a new diagnosis of GU

Timeframe: Day 1

Trial details

NCT IDNCT04761107

SponsorIcahn School of Medicine at Mount Sinai

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2026-02

View on ClinicalTrials.gov More COVID-19 Infection trials